Pulmonary mucormycosis masquerading as endobronchial tumour in an immunocompetent pregnant young lady

Khai Lip Ng1, Nai-Chien Huan1, Mona Zaria Nasaruddin1, Noorul Afidza Muhammad1, Ummi Nadira Daut2 & Jamalul Azizi Abdul Rahman1

1Department of Pulmonology, Serdang Hospital, Kajang, Malaysia.
2Department of Medicine, Universiti Putra Malaysia, Kajang, Malaysia.

Abstract

Pulmonary mucormycosis is a rare but rapidly progressing and life-threatening fungal infection, usually affecting immunocompromised patients. We report a case of a previously healthy young lady who presented with prolonged cough, weight loss, and haemoptysis. Imaging showed left hilar mass with infiltration into the left main bronchus and concurrent mediastinal lymphadenopathy. Flexible bronchoscopy revealed an endobronchial mass occluding the left main bronchus. Tumour debulking was performed using rigid bronchoscopy with cryoprobe and snares. Histopathological examination revealed inflamed tissue with fungal organism. Fungal polymerase chain reaction (PCR) confirmed Rhizopus microsporus. She was treated with two weeks of intravenous amphotericin-B with complete clinical and radiological resolution.

Introduction

Mucormycosis is a common form of fungal infection among immunocompromised patients [1,2]. Owing to its angio-invasive nature, infection can progress rapidly leading to substantial morbidity and mortality [2]. Rhizopus is the most common genus of mucormycosis that is responsible for human infections, accounting for 70–80% of all cases [3]. Seven distinct clinical presentations of mucormycosis have been described, namely: rhino-orbital-cerebral, cutaneous, pulmonary, gastrointestinal, isolated central nervous system, renal, and disseminated disease [4]. Patients with haematological malignancies, post-transplant patients, and patients with poorly controlled diabetes mellitus are particularly at risk of contracting the disease [3–5]. Rhizopus infection masquerading as endobronchial tumour is a rare clinical entity among immunocompetent patients. Here, we report a young pregnant lady with pulmonary mucormycosis masquerading as left hilar mass with endobronchial extension, leading to considerable diagnostic and therapeutic challenges. She was successfully managed with multimodality approach, incorporating endobronchial interventions and medical therapy.

Case Report

A 31-year-old lady presented with a one-month history of chronic cough, loss of weight, loss of appetite, and occasional haemoptysis (blood streaks in sputum). She reported no fever, night sweats, skin lesions, eye pain, headache, or symptoms suggestive of rhinitis. She had no known sick contact. There was no recent travelling and she is a lifetime non-smoker. She is a housewife staying in a terrace house and does not have any pets. Vital signs were stable and she did not require any supplementary oxygen. Physical examination was otherwise unremarkable other than reduced breath sounds on the left side. Bedside ultrasound showed collapsed left lung. Computed tomography showed...
left hilar mass with infiltration into the left main bronchus and mediastinal lymphadenopathy (Fig. 1A).

Flexible bronchoscopy done revealed a whitish endobronchial mass completely occluding the left main bronchus, about 2 cm from the carina (Fig. 1B). After proper counselling, rigid bronchoscopy was performed under general anaesthesia using bronchial tube, intubated into the left main bronchus. Endobronchial snaring was done (Fig. 1C). After removing the mass obstructing the left main bronchus, copious amount of secretions was observed along distal airways of the left upper and lower lobes. Unhealthy mucosa with multiple nodules was seen along the airway. Cryobiopsy of the nodules was done and argon plasma coagulation was applied on the unhealthy mucosa. Left bronchial airways were patent after procedure (Fig. 1D). The provisional diagnosis at that time was lung malignancy.

Endobronchial biopsy later revealed inflamed tissue with the presence of fungal organism. There was no granuloma and malignancy seen. The appearance favours mucormycosis/zygomycosis (Fig. 2A, B). Fungal polymerase chain reaction (PCR) shows *Rhizopus microsporus*. The patient was then treated with intravenous amphotericin-B for two weeks. Posaconazole was not given as it is classified as class C in pregnancy. Repeated chest radiography after two weeks shows complete resolution of the mass (Fig. 2C, D).

**Discussion**

Lymphoma, thymoma, thyroid mass, lung carcinoma, sarcoidosis, and teratoma can all manifest as hilar masses on chest radiographs. In our case report, the aggressive behaviour of left hilar mass together with its invasive properties (i.e. infiltration and obstruction of the left main bronchus) led to a provisional diagnosis of malignancy after initial assessment. Bronchoscopic findings of total occlusion of the left main bronchus by a necrotic mass together with the presence of multiple irregular nodules and mass post debulking further increased our suspicion that malignancy was the most likely diagnosis. To our surprise, fungal bodies were seen under the microscope during histopathological examination of endobronchial tissue samples. Malignant cells were not seen. A confirmatory diagnosis of
pulmonary mucormycosis caused by *R. microsporus* was made by using fungal PCR.

Mucormycosis is the second most frequent mould infection in immunocompromised patients and can progress rapidly in both immunocompromised and immunocompetent individuals [1,2]. The angio-invasive nature of the organism makes early diagnosis and treatment very important [2]. *Rhizopus microsporus* is commonly found in soil, plant debris, and food products such as rice and fermented food [3,5]. We attempted to identify any possible environmental exposure in our case. Our patient is a housewife. Thorough questioning has failed to reveal any possible association between environmental factors and her infection. Diagnostic evaluation of Rhizopus infection frequently requires an invasive procedure to obtain tissue samples [6]. Sputum and bronchial alveolar lavage failed to reveal any fungal growth in the patient. She had to undergo rigid bronchoscopy with debulking of the intraluminal mass to obtain adequate tissues for identifying fungal body. Advanced laboratory diagnostic testing using fungal PCR was needed to confirm *R. microsporus* [3,6].

Majority of published studies recommend intravenous lipid formulations of amphotericin-B (5 mg/kg/day) or amphotericin-B deoxycholate (0.7–1 mg/kg/day) or oral posaconazole 400 mg twice a day for the treatment of pulmonary mucormycosis [7–9]. Pregnancy status is one of the considerations when selecting antifungal therapy. Intravenous amphotericin-B (pregnancy risk class B) was selected over oral posaconazole (pregnancy risk class C) in this patient. Amphotericin-B deoxycholate was used rather than the liposomal form in this case, and the patient did not experience any side effects such as fever, chills, or adverse gastrointestinal reactions. She was treated for two weeks of intravenous antifungal therapy, given via central venous catheter. As there was complete resolution of radiological changes after treatment with intravenous amphotericin-B for two weeks, the decision was to discontinue the antifungal therapy.

Although rare, mucormycosis has been reported among immunocompetent patients. Mignogna et al. published a case series involving five immunocompetent patients with mucormycosis of maxillary sinuses while Lee et al. reported a
case of pulmonary mucormycosis in a patient with chronic obstructive pulmonary disease using inhaled corticosteroid [10,11]. Ramirez et al., on the other hand, reported a pregnant lady with diabetes mellitus who developed pulmonary mucormycosis in her third trimester of pregnancy [12]. She was subjected to intravenous amphotericin-B followed by right middle and lower lobectomy due to extensive disease. Our patient, however, was fortunately successfully managed with endoscopic procedures together with intravenous antifungal agent without requiring emergency airway surgery or lung resection. We further explored on whether our patient’s pregnancy status increased her susceptibility to infections. A systematic review conducted by Sappenfield et al. concluded that immune alterations in pregnancy may impair pathogen clearance leading to increased severity of disease for several pathogens such as influenza, malaria, and herpes simplex infection [13]. However, it remains unknown on whether pregnancy can increase the risk of pulmonary mucormycosis.

In conclusion, pulmonary mucormycosis should be considered in young patients with no risk factor for malignancy presented with left hilar mass as part of the differential diagnosis. A more proactive approach to obtain a diagnosis is important as it is potentially curable if treated early. Intravenous amphotericin-B remains the most recommended antifungal for pregnant patients with mucormycosis.

Disclosure Statement

Appropriate written informed consent was obtained for publication of this case report and accompanying images.

Acknowledgements

We would like to thank Dr Sanusi Zulkifli from Medical Department of University Putra Malaysia and Dr Noriah Othman and her dedicated team at the Department of Pathology Serdang Hospital for their efforts and contribution towards the care of the patient.

References

1. Fernandez JF, Maselli DJ, Simpson T, et al. 2013. Pulmonary mucormycosis: what is the best strategy for therapy? Respir. Care 58(5):e60–e63.
2. Lee FYW, Mossad SB, and Adal KA. 1999. Pulmonary mucormycosis: the last 30 years. Arch. Intern. Med. 159(12):1301–1309.
3. Gomes MZR, Lewis RE, and Kontoyiannis DP. 2011. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin. Microbiol. Rev. 24(2):411–445.
4. Wang XM, Guo LC, Xue SL, et al. 2016. Pulmonary mucormycosis: a case report and review of the literature. Oncol. Lett. 11(5):3049–3053.
5. Muqetadnan M, Rahman A, Amer S, et al. 2012. Pulmonary mucormycosis: an emerging infection. Case Rep. Pulmonol. 2012:1–3.
6. Tsyrkunou AV, Ellison RT, Akalin A, et al. 2014. Multifocal Rhizopus microsporus lung infection following brush clearing. Med. Mycol. Case Rep. 6:14–17.
7. Limper AH, Knox KS, Sarosi GA, et al. 2011. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am. J. Respir. Crit. Care Med. 183:96–128.
8. Spellberg B, Walsh TJ, Kontoyiannis DP, et al. 2009. Recent advance in the management of mucormycosis: from bench to bedside. Clin. Infect. Dis. 48:1743–1751.
9. Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. 2019. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect. Dis. 19(12):e405–e421.
10. Mignogna MD, Fortuna G, Leuci S, et al. 2011. Mucormycosis in immunocompetent patients: a case-series of patients with maxillary sinus involvement and a critical review of the literature. J. Infect. Dis. 15(8):e533–e540.
11. Lee JS, Kim HC, Park SW, et al. 2013. A case of isolated pulmonary mucormycosis in an immunocompetent host. Tuberc. Respir. Dis. 74(6):269–273.
12. Ramirez JL, Urisman A, Kukreja J, et al. 2018. Surgical management of pulmonary mucormycosis in third-trimester pregnancy. Thorac. Cardiovasc. Surg. Rep. 7(1):e27–e29.
13. Sappenfield E, Jamieson DJ, and Kourtis AP. 2013. Pregnancy and susceptibility to infectious diseases. Infect. Dis. Obstet. Gynecol. 2013:752852. https://doi.org/10.1155/2013/752852.